Clinical Trials Browser

Approved for marketing × INDUSTRY × asparaginase erwinia chrysanthemi recombinant × Clear all

NCT04943952 2021-08-03

JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

Approved for marketing

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma